Controversial data exists concerning the impact of immunosuppressive therapy on the development of post-transplantation diabetes mellitus.
Dr Martin Stockmann and colleagues from Germany investigated glucose metabolism in living-donor liver transplants.
The team assessed 18 healthy donors and recipients, without pre-existing diabetes mellitus before, on day 10, month 6, and month 12 after intervention.
Computer-assisted analysis of glucose, insulin, and C-peptide profiles were obtained from frequently sampled intravenous glucose tolerance tests .
Insulin sensitivity data from first and second phase insulin secretion were also obtained.
|Insulin sensitivity of recipients increased after living-donor liver transplants|
The research team found that insulin sensitivity of donors declined by day 10 after operation but returned to values as before after 6 months.
Phase 1 of insulin secretion did not change, however, phase 2 significantly increased by day 10, and after 6 months, returned in the same range as before.
The researcher noted that, in parallel to donors, insulin sensitivity of recipients progressively increased after living-donor liver transplants.
Phase 1 of insulin secretion did not alter in recipients.
The team observed that phase 2 continuously decreased and was not different from donors by month 12.
The extent of liver injury was assessed by liver enzyme concentrations.
The researchers evaluated liver function represented by cholinesterase activity.
Albumin, and international normalized ratio were closely related with changes of insulin sensitivity in donors and recipients during the first year after intervention.
Dr Stockmann's team concluded, “The extent of liver damage plays a predominant role in regulating glucose tolerance.”
“No impact of immunosuppressive therapy on insulin sensitivity, phase 1 and 2 of insulin secretion, was detected.”